SHARMEH P/E Ratio
Current P/E Ratio
26.71
High Valuation
High - Growth expectations or overvalued
SHARMEH (SHARMEH) P/E ratio is 26.71 (High), EPS (TTM) ₹3.79, current price ₹108.18 on BSE — High - Growth expectations or overvalued. Browse SHARMEH cash flow statement for revenue, profit, balance sheet and cash flow data.
Current Valuation Metrics
P/E Ratio
26.71
Current Price
₹108.18
EPS (TTM)
₹3.79
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
68.22
Sector Median
45.42
Sector Rank
#11 of 56
Sector Percentile
19.6%
SHARMEH P/E Ratio — Valuation Signal & Historical Context
SHARMEH P/E 26.71 — signal: Overvalued. Analyse SHARMEH promoter holding to track promoter, FII and institutional holdings.
- Stock appears overvalued with PE of 26.71, suggesting caution for new investments
- Trading at discount to sector average PE of 68.22
SHARMEH vs Healthcare Services Peers — P/E Ratio Comparison
SHARMEH P/E 26.71 vs Healthcare Services average 68.22, median 45.42 — range 7.98–460.81.
Sector Average
68.22
Sector Median
45.42
Lowest P/E
7.98
Highest P/E
460.81
Companies
56
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Star Imaging And Path Lab | STARIMAGIN | 7.98 | ₹125 | Low |
| Shanmuga Hospital | SHANMUGA | 12.91 | ₹54 | Low |
| Nidan Labs & Healthcare | NIDAN | 13.47 | ₹20 | Low |
| Deccan Health Care | DECCAN | 14.18 | ₹32 | Low |
| One Global Service Provi… | ONEGLOBAL | 14.84 | ₹920 | Low |
| Abate AS Industries | ABATEAS | 14.93 | ₹162 | Low |
| Invicta Diagnostic | INVICTA | 17.24 | ₹80 | Moderate |
| 3B BlackBio DX | 3BBLACKBIO | 17.7 | ₹1,061 | Moderate |
| Indraprastha Medical Cor… | INDRAMEDCO | 17.93 | ₹3,334 | Moderate |
| Dr Lalchandani Labs | DLCL | 19.85 | ₹8 | Moderate |